Diabetes patients who used Ozempic were more than twice as likely to be diagnosed with the rare condition, called NAION, than those who took another type of diabetes drug, according to a team of researchers who studied years of patient records from Denmark and Norway. The study wasn’t able to determine whether there was a similar impact among people taking Ozempic’s sister drug, Wegovy, for obesity.
The ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.